HAYA Therapeutics gets $65M for 'dark genome' work following last year's Lilly pact
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back with $65 million to get its cardiac fibrosis treatment candidate into human trials. ...
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back with $65 million to get its cardiac fibrosis treatment candidate into human trials. ...
